                         SEQUENCE LISTING

<110>  F. Hoffmann-La Roche AG
 
<120>  Process for the preparation of a petide powder form

<130>  Case 25735

<150>  EP 08172689.5
<151>  2008-12-23

<160>  3     

<170>  PatentIn version 3.5

<210>  1
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is Aib

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Xaa is Aib

<400>  1

His Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 
1               5                   10                  15      


Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Xaa Arg 
            20                  25                  30  


<210>  2
<211>  39
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized Peptide

<400>  2

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 
1               5                   10                  15      


Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 
            20                  25                  30          


Ser Gly Ala Pro Pro Pro Ser 
        35                  


<210>  3
<211>  44
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide

<400>  3

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 
1               5                   10                  15      


Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 
            20                  25                  30          


Ser Gly Ala Pro Pro Ser Lys Lys Lys Lys Lys Lys 
        35                  40                  


